vermonthas.blogg.se

Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1.Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022.Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program.Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD.Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis.FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence.Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity.Press Release: Availability of the Q1 2022 Memorandum for modelling purposes.Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets.Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver.Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment.Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis.

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis.Nirsevimab significantly protected infants against RSV disease in Phase 3 trial.